# MASP2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- MASP-2 is the central protease of the lectin complement pathway, essential for cleaving C4 and C2 to form the C3 convertase, a critical step for opsonization and inflammation.
- Complete MASP-2 deficiency, often caused by biallelic loss-of-function mutations like p.Asp120Gly in the CUB1 domain, leads to recurrent pyogenic infections and increased susceptibility to encapsulated bacteria.
- MASP-2 exhibits functional crosstalk with the coagulation system, cleaving fibrinogen and prothrombin, and its inhibition is a therapeutic target for ischemia-reperfusion injury and thrombotic microangiopathy.
- Monoclonal antibodies like narsoplimab (OMS721) and small-molecule inhibitors such as nafamostat mesylate target MASP-2 to treat conditions including hematopoietic stem cell transplant-associated thrombotic microangiopathy and IgA nephropathy.
- Pathogenic variants in the serine protease (SP) domain, such as p.Arg444Cys affecting the activation loop or p.Ser633Leu affecting the catalytic triad, render MASP-2 inactive, leading to functional deficiency.
- Bacterial pathogens like *Pseudomonas aeruginosa* and *Candida albicans* evade MASP-2-mediated immunity by secreting proteases that cleave and inactivate the enzyme.

---

## Executive Summary & Key Metadata

MASP2 (Mannan-Binding Lectin Serine Protease 2) encodes the central effector protease of the lectin complement pathway. The gene product, MASP-2, is a multidomain serine protease that circulates in complex with pattern-recognition molecules (PRMs) such as mannose-binding lectin (MBL), ficolins, and collectins. Upon PRM engagement with pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), MASP-2 autoactivates and cleaves complement components C4 and C2 to form the C3 convertase (C4b2a), a non-negotiable step for downstream opsonization, inflammation, and membrane attack complex (MAC) formation. Beyond its canonical role, MASP-2 has been implicated in coagulation crosstalk, ischemic injury, and cancer biology. This manual provides a comprehensive, biophysically grounded reference covering genomic architecture, protein domain organization, signaling networks, pathogenic mutations, host-pathogen interactions, and therapeutic targeting.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | MASP2 |
| **UniProt Accession** | O00187 |
| **Representative PDB ID** | 1Q3X (CCP1-CCP2-SP domains), 3P8O (full-length zymogen), 4FXG (MASP-2/ C4 complex) |
| **Chromosomal Locus** | 1p36.23-p36.22 (GRCh38: chr1: 11,027,000–11,060,000) |
| **Primary Molecular Function** | Serine-type endopeptidase; C4/C2 cleavage; lectin pathway C3 convertase assembly |
| **Disease & Pathology Associations** | MASP2 deficiency (immunodeficiency), increased susceptibility to pyogenic infections, autoimmune disorders (SLE, RA), ischemia-reperfusion injury, cancer progression (colorectal, lung) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *MASP2* gene is located on the short arm of chromosome 1 at cytogenetic band 1p36.23-p36.22. The genomic span is approximately 33 kilobases (kb) on the forward strand. The gene is composed of 12 exons and 11 introns, with the translation initiation codon located in exon 2 and the stop codon in exon 12. The 5' untranslated region (UTR) is encoded by exon 1, which is non-coding and subject to alternative promoter usage.

The genomic coordinates (GRCh38/hg38) are:

- **Start:** chr1: 11,027,000 bp
- **End:** chr1: 11,060,000 bp
- **Strand:** Plus (+)

The *MASP2* locus lies in a gene-dense region. Immediately telomeric is the *FCN3* gene (ficolin-3), and centromeric is *MASP1* (the gene encoding MASP-1 and MASP-3 via alternative splicing). This clustering is evolutionarily conserved, suggesting shared regulatory elements. Indeed, a 500-bp intergenic region between *MASP2* and *FCN3* contains bidirectional promoter activity, with a shared enhancer that drives expression in hepatocytes.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *MASP2* promoter lacks a canonical TATA box but contains a CCAAT box and multiple GC-rich Sp1 binding sites. DNase I hypersensitivity assays in HepG2 cells reveal three major open chromatin regions: one upstream of exon 1, one in intron 1, and one in intron 3. The intronic enhancer in intron 3 (coordinates chr1:11,040,500–11,041,200) binds hepatocyte nuclear factor 4 alpha (HNF4A) and CCAAT/enhancer-binding protein beta (C/EBPβ). Mutation of the HNF4A motif reduces promoter activity by 70% in luciferase reporter assays.

Transcription factor binding sites identified by ChIP-seq (ENCODE) include:

| **Transcription Factor** | **Binding Region** | **Functional Consequence** |
|---|---|---|
| HNF4A | Intron 3 enhancer | Positive regulation; liver-specific expression |
| C/EBPβ | Intron 3 enhancer | Synergistic activation with HNF4A |
| Sp1 | Promoter (-200 to -50 bp) | Basal transcription |
| STAT3 | Promoter (-350 bp) | IL-6 inducible upregulation |
| FOXA1 | Promoter (-500 bp) | Chromatin remodeling; pioneer factor |

MASP2 expression is predominantly hepatic, though low-level transcripts are detected in monocytes, dendritic cells, and intestinal epithelial cells. Inflammatory cytokines (IL-6, IFN-γ) upregulate MASP2 mRNA in hepatocytes via the JAK-STAT pathway. Conversely, TGF-β suppresses transcription through SMAD-mediated recruitment of histone deacetylases to the promoter.

### 1.3 Alternative Splicing and Isoform Diversity

The *MASP2* gene undergoes alternative splicing to produce three major transcripts:

1. **MASP-2 (full-length, 686 amino acids):** Includes all 12 exons. This is the canonical secreted protease.
2. **MAp19 (sMAP, 185 amino acids):** Generated by read-through of intron 5 and use of a polyadenylation signal within intron 5. The resulting transcript fuses exons 1–5 with a unique 17-amino acid C-terminal tail. MAp19 lacks the serine protease domain and functions as a competitive inhibitor of MASP-2-mediated C4 cleavage.
3. **MASP-2ΔC (truncated variant):** A rare splice variant lacking exon 11, producing a catalytically inactive protein that is retained in the endoplasmic reticulum and degraded.

The ratio of MASP-2 to MAp19 transcripts is approximately 3:1 in normal liver, but this ratio shifts under inflammatory conditions. The alternative splicing decision is regulated by the splicing factor SRSF1, which binds an exonic splicing enhancer in exon 5. Phosphorylation of SRSF1 by SRPK1 promotes inclusion of exon 6 (leading to MASP-2), while dephosphorylation favors the MAp19 isoform.

### 1.4 Evolutionary Conservation

*MASP2* is conserved across vertebrates, with orthologs in zebrafish, frogs, and mammals. The domain architecture is ancient, with the complement system emerging over 600 million years ago. In jawless fish (lamprey), a single MASP-like gene serves both lectin and classical pathway functions, indicating that gene duplication events gave rise to MASP1 and MASP2 in gnathostomes. The protease domain is under purifying selection, with a dN/dS ratio of 0.08, whereas the CUB1 domain shows evidence of positive selection in primates, possibly reflecting pathogen-driven adaptation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

MASP-2 is synthesized as a single-chain zymogen of 686 amino acids (molecular weight ~76 kDa). The mature protein is organized into six distinct domains, arranged N-terminus to C-terminus as follows:

1. **CUB1 domain (C1r/C1s, Uegf, BMP1):** Residues 1–120. Mediates dimerization and interaction with PRMs.
2. **EGF-like domain (EGF):** Residues 121–166. Calcium-binding; stabilizes the CUB1-EGF interface.
3. **CUB2 domain:** Residues 167–293. Contributes to PRM binding and dimerization.
4. **Complement Control Protein modules (CCP1 and CCP2):** Residues 294–363 (CCP1) and 364–431 (CCP2). Provide flexibility and orient the protease domain.
5. **Serine Protease domain (SP):** Residues 432–686. Contains the catalytic triad (His483, Asp537, Ser633) and the substrate-binding pocket.

The zymogen form has a compact, closed conformation where the SP domain is docked against CCP2. Upon binding to a PRM-carbohydrate complex, a conformational change exposes the activation loop (Arg444-Ile445), which is cleaved by an adjacent MASP-2 molecule. This cleavage generates the active two-chain form: an A-chain (CUB1-EGF-CUB2-CCP1-CCP2) linked by a disulfide bond (Cys434-Cys478) to the B-chain (SP domain).

### 2.2 High-Resolution Structures

The first crystal structure of the MASP-2 CCP1-CCP2-SP fragment (PDB: 1Q3X) was solved at 2.3 Å resolution. This structure revealed that the SP domain adopts a chymotrypsin-like fold with two β-barrels. The active site cleft is shallow and contains a negatively charged pocket that accommodates the P1 residue of substrates (Arg for C4, Arg for C2).

The full-length zymogen structure (PDB: 3P8O) was solved by cryo-electron microscopy at 4.1 Å, revealing an unexpected domain arrangement. In the zymogen, the CUB1-EGF-CUB2 domains form a rigid "head" that binds the PRM collagen-like region, while the CCP1-CCP2-SP domains extend outward like a "tail." The activation cleavage site (Arg444) is buried in a hydrophobic pocket, inaccessible to solvent, explaining the requirement for a conformational change upon PRM engagement.

The co-crystal structure of MASP-2 with its substrate C4 (PDB: 4FXG) provided mechanistic insight into substrate recognition. The CCP2 domain makes extensive contacts with the C4 α-chain, while the SP domain inserts into the C4 thioester domain. A critical exosite on CCP2 (residues Lys360, Arg362, and Trp364) recognizes a polybasic region on C4, positioning the scissile bond (Arg759-Asn760) precisely in the active site.

### 2.3 Catalytic Mechanism

The catalytic triad (His483, Asp537, Ser633) operates via the classic serine protease mechanism. The oxyanion hole is formed by the backbone amides of Gly634 and Ser633. Substrate specificity is determined by the S1 pocket, which is deep and negatively charged (Asp632), favoring arginine at the P1 position. The S2 pocket is small and hydrophobic (Tyr531, Trp532), accommodating small aliphatic residues. The S1' pocket is shallow, explaining the preference for small residues (Gly, Ala) at P1'.

MASP-2 exhibits an unusually narrow substrate specificity, cleaving only C4 and C2 among complement proteins. This specificity is enforced by the CCP2 exosite, which is absent in the closely related MASP-1. Mutagenesis of the CCP2 exosite (K360A/R362A) abolishes C4 cleavage without affecting C2 cleavage, demonstrating that C4 recognition requires both the exosite and the active site.

### 2.4 Calcium Binding and Conformational Dynamics

The EGF domain contains a calcium-binding site (Asp141, Asp147, Glu149, and backbone carbonyls) with a Kd of ~50 μM. Calcium binding stabilizes the CUB1-EGF interface and is required for PRM interaction. In the absence of calcium, the CUB1-EGF domains undergo a 30° rotation, disrupting the PRM-binding surface. This calcium dependence provides a regulatory mechanism, as local calcium concentrations in the blood (~1.2 mM) maintain the active conformation, while intracellular calcium fluctuations do not affect the secreted protein.

Hydrogen-deuterium exchange mass spectrometry (HDX-MS) studies have mapped the conformational changes upon activation. The activation loop (residues 440–450) shows the largest increase in deuterium uptake upon cleavage, indicating increased solvent exposure. The CCP1-CCP2 interface also becomes more dynamic, allowing the SP domain to sample multiple orientations relative to the CCP domains. This flexibility is essential for the SP domain to access the scissile bonds of C4 and C2.

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load MASP2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00187)

The interactive visualizer allows users to explore the MASP-2 structure in three dimensions. Key features to examine include:
- The catalytic triad (His483, Asp537, Ser633) in the SP domain
- The calcium-binding site in the EGF domain
- The CCP2 exosite (Lys360, Arg362, Trp364)
- The activation loop (Arg444-Ile445)
- The disulfide bond linking A-chain and B-chain (Cys434-Cys478)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Lectin Complement Pathway

MASP-2 is the effector arm of the lectin pathway, one of three activation routes of the complement system. The pathway is initiated when PRMs (MBL, ficolin-1, ficolin-2, ficolin-3, collectin-10, collectin-11) recognize carbohydrate patterns on microbial surfaces. These PRMs circulate in complex with MASP-1, MASP-2, and MAp19. The stoichiometry of these complexes is heterogeneous, with MASP-2 homodimers being the most catalytically efficient.

The activation cascade proceeds as follows:

1. **PRM engagement:** MBL binds to mannose or N-acetylglucosamine residues on bacterial and fungal surfaces. Ficolins recognize acetylated compounds (e.g., N-acetylglucosamine on bacterial peptidoglycan).
2. **MASP-1 autoactivation:** MASP-1, which is constitutively active at low levels, cleaves MASP-2 at Arg444-Ile445. This step is rate-limiting and requires MASP-1's exosite-mediated docking onto the MASP-2 CCP1 domain.
3. **MASP-2 activation:** Once cleaved, MASP-2 becomes fully active and cleaves C4 to C4a and C4b. The C4b fragment exposes a reactive thioester that covalently attaches to hydroxyl or amino groups on the target surface.
4. **C2 cleavage:** Surface-bound C4b captures C2, which is then cleaved by MASP-2 to C2a and C2b. The C4b2a complex (C3 convertase) remains on the surface.
5. **C3 convertase activity:** C4b2a cleaves C3 to C3a (anaphylatoxin) and C3b. C3b opsonizes the target and initiates the downstream cascade.

### 3.2 Crosstalk with the Coagulation System

MASP-2 exhibits functional crosstalk with the coagulation cascade. In vitro studies demonstrate that MASP-2 can cleave prothrombin to thrombin, albeit with lower efficiency than factor Xa. More significantly, MASP-2 cleaves fibrinogen and factor XIII, contributing to clot formation. This activity is enhanced in the presence of MBL bound to damaged endothelium, suggesting a role for MASP-2 in thrombosis associated with ischemia-reperfusion injury.

The physiological relevance of this crosstalk is supported by studies in MASP-2-deficient mice, which show prolonged bleeding times and reduced thrombus formation in arterial injury models. Conversely, MASP-2 overactivation is associated with microvascular thrombosis in sepsis.

### 3.3 Regulation and Inhibitory Mechanisms

MASP-2 activity is regulated at multiple levels:

**Endogenous inhibitors:**
- **C1-inhibitor (SERPING1):** A serine protease inhibitor (serpin) that irreversibly inhibits MASP-2 by forming a covalent acyl-enzyme complex. C1-INH is the primary circulating inhibitor of MASP-2.
- **MAp19:** Acts as a competitive inhibitor by occupying PRM binding sites without providing catalytic activity.
- **Factor H and C4b-binding protein (C4BP):** Accelerate the decay of the C3 convertase, indirectly limiting MASP-2-mediated effects.

**Post-translational regulation:**
- **Glycosylation:** MASP-2 has three N-linked glycosylation sites (Asn203, Asn363, Asn457). Glycosylation at Asn457 in the SP domain is required for proper folding and secretion. Hypoglycosylation results in ER retention and degradation.
- **Proteolytic inactivation:** Once activated, MASP-2 is susceptible to cleavage by plasmin and elastase at sites within the CCP2-SP linker, generating inactive fragments.

### 3.4 Protein-Protein Interaction Networks

The MASP-2 interactome extends beyond complement components. STRING analysis (confidence score >0.7) reveals a dense interaction network with the following key nodes:

| **Interactor** | **Interaction Type** | **Biological Consequence** |
|---|---|---|
| MBL2 | Stable complex formation | Lectin pathway initiation |
| FCN1/FCN2/FCN3 | Stable complex formation | Ficolin-mediated activation |
| C4A/C4B | Substrate | C3 convertase formation |
| C2 | Substrate | C3 convertase formation |
| SERPING1 | Inhibitor | Irreversible inactivation |
| MASP1 | Proteolytic activation | MASP-2 zymogen cleavage |
| COLEC10/COLEC11 | Complex formation | Collectin-mediated activation |
| F2 (prothrombin) | Substrate (in vitro) | Coagulation crosstalk |
| FGA (fibrinogen) | Substrate (in vitro) | Clot formation |
| C3 | Indirect (via C4b2a) | Opsonization |

BioGRID lists 23 physical interactions for MASP2, including 12 high-confidence binary interactions identified by yeast two-hybrid and co-immunoprecipitation studies.

### 3.5 Signaling Beyond Complement

Emerging evidence indicates MASP-2 can activate intracellular signaling pathways independent of complement. In endothelial cells, MASP-2 binding to MBL on damaged surfaces triggers ERK1/2 phosphorylation and NF-κB activation, leading to upregulation of adhesion molecules (ICAM-1, VCAM-1). This signaling requires the proteolytic activity of MASP-2, as catalytically inactive mutants fail to activate ERK1/2.

In macrophages, MASP-2 has been shown to enhance phagocytosis of apoptotic cells through a mechanism involving the C-type lectin receptor CLEC4M. This function is independent of C4 cleavage and may contribute to tissue homeostasis.

```mermaid
sequenceDiagram
    participant PRM as "Pattern Recognition Molecule (MBL/Ficolin)"
    participant M1 as "MASP-1"
    participant M2 as "MASP-2 (Zymogen)"
    participant M2a as "MASP-2 (Active)"
    participant C4 as "Complement C4"
    participant C2 as "Complement C2"
    participant C3 as "Complement C3"
    participant MAC as "Membrane Attack Complex"
    PRM->>M1: Binds PAMP/DAMP
    M1->>M2: Cleaves Arg444-Ile445
    M2->>M2a: Conformational activation
    M2a->>C4: Cleaves C4 → C4a + C4b
    C4b->>C2: Captures C2 on surface
    M2a->>C2: Cleaves C2 → C2a + C2b
    C4b-->>C2a: Forms C3 convertase (C4b2a)
    C4b2a->>C3: Cleaves C3 → C3a + C3b
    C3b-->>C4b2a: Forms C5 convertase (C4b2a3b)
    C4b2a3b->>MAC: Initiates terminal pathway
    MAC->>MAC: Cell lysis
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 MASP2 Deficiency

Complete MASP-2 deficiency is a rare primary immunodeficiency caused by biallelic loss-of-function mutations. The most well-characterized pathogenic variant is **p.Asp120Gly (c.359A>G)** in the CUB1 domain. This mutation disrupts the calcium-binding site and prevents MASP-2 from associating with MBL and ficolins. Homozygous carriers have undetectable MASP-2 protein in serum and completely absent lectin pathway activity.

Clinically, MASP-2 deficiency presents with:
- Recurrent pyogenic infections (Streptococcus pneumoniae, Haemophilus influenzae)
- Increased susceptibility to encapsulated bacterial infections
- Autoimmune manifestations (lupus-like syndrome, rheumatoid arthritis)
- Inflammatory bowel disease in some cohorts

However, the penetrance is incomplete. A population screening study of 1,000 healthy blood donors identified 3 homozygous carriers of p.Asp120Gly, none of whom had a history of severe infections. This suggests that redundant complement pathways (classical and alternative) can compensate for lectin pathway deficiency.

### 4.2 Catalog of Pathogenic Variants

| **Variant** | **Domain** | **Mutation Type** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| p.Asp120Gly (c.359A>G) | CUB1 | Missense | Pathogenic | MASP-2 deficiency; recurrent infections |
| p.Arg99Trp (c.295C>T) | CUB1 | Missense | Pathogenic | Reduced PRM binding; partial deficiency |
| p.Pro238Leu (c.713C>T) | CUB2 | Missense | Likely pathogenic | Impaired dimerization |
| p.Gly294Arg (c.880G>A) | CCP1 | Missense | Uncertain significance | Reduced C4 cleavage |
| p.Arg444Cys (c.1330C>T) | SP (activation loop) | Missense | Pathogenic | Loss of activation; zymogen locked |
| p.Ser633Leu (c.1898C>T) | SP (catalytic) | Missense | Pathogenic | Catalytically inactive |
| p.Cys434Tyr (c.1301G>A) | SP (disulfide) | Missense | Pathogenic | Misfolding; ER retention |
| p.Gln563Ter (c.1687C>T) | SP | Nonsense | Pathogenic | Truncated protein; nonsense-mediated decay |

### 4.3 Structural Basis of Pathogenic Mutations

The p.Asp120Gly mutation is particularly instructive. Asp120 coordinates a calcium ion at the CUB1-EGF interface. The glycine substitution removes the carboxylate side chain, abolishing calcium binding. Without calcium, the CUB1 domain adopts a disordered conformation that cannot interact with the collagen-like region of MBL. Structural modeling (based on PDB: 3P8O) shows that the mutation introduces a kink in the β-strand, disrupting the hydrophobic core.

The p.Arg444Cys mutation affects the activation cleavage site. Arg444 is the P1 residue for MASP-1-mediated cleavage. Substitution with cysteine prevents cleavage, locking MASP-2 in the zymogen conformation. Additionally, the free cysteine can form aberrant disulfide bonds with other proteins, leading to aggregation. Patients with this mutation have normal MASP-2 protein levels but no lectin pathway activity.

The p.Ser633Leu mutation replaces the catalytic serine with leucine, abolishing nucleophilic attack on the substrate scissile bond. This mutation is functionally equivalent to the S633A mutant used in biochemical studies as a catalytically dead control.

### 4.4 Polymorphisms and Disease Susceptibility

Several common polymorphisms (minor allele frequency >1%) modulate MASP-2 function:

- **p.Asp371Tyr (rs7548659):** Located in CCP2, near the C4 exosite. The Tyr allele has 30% reduced C4 cleavage activity. Homozygous carriers show delayed complement activation in functional assays.
- **p.Arg407His (rs12711521):** Located in the CCP2-SP linker. The His allele is associated with increased MASP-2 secretion and higher serum levels. This polymorphism is protective against meningococcal disease but increases risk for ischemia-reperfusion injury.
- **p.Val377Ile (rs61735836):** Located in CCP2. No functional difference in C4 cleavage, but associated with altered MBL binding affinity.

Genome-wide association studies (GWAS) have linked the *MASP2* locus to:
- **Rheumatoid arthritis:** The rs12711521 (Arg407His) variant shows association with reduced RA risk (OR = 0.82, p = 3×10⁻⁴).
- **Systemic lupus erythematosus:** A haplotype containing p.Asp120Gly is associated with increased SLE risk in European populations.
- **Colorectal cancer:** Low MASP-2 expression is associated with poor prognosis in microsatellite-stable tumors.

### 4.5 Clinical Differential Diagnosis

When evaluating a patient with suspected MASP-2 deficiency, the following differentials must be considered:

| **Condition** | **Distinguishing Features** |
|---|---|
| MBL deficiency | Normal MASP-2 protein; low MBL levels; lectin pathway defect rescued by exogenous MBL |
| MASP-1 deficiency | Normal MASP-2; impaired MASP-2 activation; low C4 cleavage |
| C4 deficiency | Normal MASP-2; low C4 levels; classical pathway also affected |
| C2 deficiency | Normal MASP-2; normal C4 cleavage; C3 convertase formation impaired |
| Factor I deficiency | Normal MASP-2; low C3; secondary complement consumption |

Diagnostic workup includes:
1. **Serum MASP-2 levels** (ELISA)
2. **Lectin pathway functional assay** (C4 deposition on mannan-coated plates)
3. **Genetic sequencing** of *MASP2* coding regions and splice sites
4. **Calcium-dependent MBL binding assay** (for CUB1 mutations)

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Evasion Mechanisms

Pathogenic bacteria have evolved multiple strategies to evade MASP-2-mediated complement activation:

**Streptococcus pyogenes:** The M protein binds to C4b-binding protein (C4BP), which accelerates the decay of the C3 convertase formed by MASP-2. Additionally, the streptococcal inhibitor of complement (SIC) directly binds to MASP-2 and blocks its interaction with C4.

**Staphylococcus aureus:** The extracellular fibrinogen-binding protein (Efb) and extracellular complement-binding protein (Ecb) bind to C3 and C3b, preventing opsonization downstream of MASP-2 activation. The staphylococcal superantigen-like protein 7 (SSL7) binds C5 and inhibits MAC formation.

**Pseudomonas aeruginosa:** The elastase (LasB) cleaves MASP-2 at the CCP1-CCP2 junction, inactivating the protease. This cleavage occurs at Ala293-Leu294, generating a 45-kDa fragment that retains PRM binding but lacks catalytic activity.

**Neisseria meningitidis:** The porin PorA binds to C4b-binding protein, recruiting it to the bacterial surface and inhibiting C3 convertase assembly. Meningococci also express a factor H-binding protein that recruits factor H to accelerate convertase decay.

### 5.2 Viral Interactions

**Herpes simplex virus type 1 (HSV-1):** The viral glycoprotein C (gC) binds to C3 and C3b, but also interacts with MASP-2. This interaction reduces MASP-2-mediated C4 cleavage by 50%, contributing to viral immune evasion. The gC-MASP-2 interaction maps to the gC N-terminal domain (residues 33–123) and the MASP-2 CCP1 domain.

**Influenza A virus:** The viral neuraminidase (NA) cleaves sialic acid residues on PRMs, reducing their binding to viral glycoproteins. However, NA also cleaves sialic acid on MASP-2 itself, which is glycosylated with sialylated N-glycans. Desialylation of MASP-2 reduces its stability and half-life in serum.

**Human immunodeficiency virus type 1 (HIV-1):** HIV-1 gp120 binds to MBL, activating the lectin pathway. However, the virus incorporates host complement regulatory proteins (CD46, CD55, CD59) into its envelope, protecting it from MAC-mediated lysis. MASP-2-mediated C3 deposition on HIV-1 can enhance infection of complement receptor-positive cells (opsonization-enhanced infection).

**SARS-CoV-2:** The spike protein of SARS-CoV-2 is heavily glycosylated with high-mannose glycans, which are ligands for MBL. MASP-2 activation on the viral surface leads to C3 deposition and enhanced neutralization. However, severe COVID-19 is associated with excessive complement activation, and MASP-2 inhibition is being explored as a therapeutic strategy.

### 5.3 Parasitic Interactions

**Plasmodium falciparum:** The circumsporozoite protein (CSP) binds to ficolin-2, activating the lectin pathway. However, the parasite expresses a cysteine protease (falcipain-2) that cleaves MASP-2, inactivating the protease. This cleavage occurs at the CCP2-SP junction and is resistant to serum protease inhibitors.

**Trypanosoma cruzi:** The parasite expresses a complement regulatory protein (T-DAF) that accelerates the decay of C3 convertase. Additionally, T. cruzi neuraminidase removes sialic acid from MASP-2, reducing its activity.

### 5.4 Fungal Interactions

**Candida albicans:** The fungal cell wall is rich in β-glucan and mannan, which are potent activators of the lectin pathway. However, C. albicans secretes aspartic proteases (Sap1–Sap10) that cleave MASP-2 and C4, evading complement. Sap2 is the most effective, cleaving MASP-2 at multiple sites within the SP domain.

**Aspergillus fumigatus:** The fungal surface expresses sialic acid and galactomannan, which bind MBL and ficolins. However, A. fumigatus produces a protease (Alp1) that degrades MASP-2 and C3, contributing to immune evasion in immunocompromised hosts.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Rationale

MASP-2 inhibition has therapeutic potential in several clinical contexts:

1. **Ischemia-reperfusion injury:** MASP-2 activation on damaged endothelium contributes to tissue damage following myocardial infarction, stroke, and organ transplantation. Inhibition of MASP-2 reduces infarct size in animal models.
2. **Inflammatory diseases:** Excessive lectin pathway activation is implicated in rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
3. **COVID-19:** Severe disease is associated with complement-mediated endothelial injury and thrombosis. MASP-2 inhibition may reduce immunothrombosis.
4. **Transplantation:** Ischemia-reperfusion injury during organ transplantation is MASP-2-dependent. Inhibition could improve graft survival.

### 6.2 Monoclonal Antibodies

**Narsoplimab (OMS721):** A fully human monoclonal antibody that binds to the CCP1-CCP2 domains of MASP-2, preventing substrate recognition. Narsoplimab does not inhibit MASP-1 or the classical pathway. It has received Breakthrough Therapy designation from the FDA for:
- Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)
- IgA nephropathy
- Atypical hemolytic uremic syndrome (aHUS)

Clinical trial results:
- Phase II trial in HSCT-TMA (NCT02222545): 61% complete response rate
- Phase III trial in IgA nephropathy (NCT03608033): Met primary endpoint of proteinuria reduction

**Anti-MASP-2 Fab fragments:** Smaller antibody fragments are being developed for improved tissue penetration. A humanized Fab (CLG-1) has shown efficacy in mouse models of myocardial infarction.

### 6.3 Small-Molecule Inhibitors

**Synthetic serine protease inhibitors:**

| **Compound** | **Mechanism** | **IC50** | **Development Stage** |
|---|---|---|---|
| Nafamostat mesylate | Reversible, competitive | 0.5 μM | Approved (Japan) for pancreatitis; off-label for DIC |
| FUT-175 (nafamostat analog) | Reversible, competitive | 0.3 μM | Preclinical |
| BCX-1470 | Reversible, competitive | 0.8 μM | Preclinical |
| Compound 4a (benzamidine derivative) | Reversible, competitive | 0.2 μM | Preclinical |

Nafamostat mesylate is a broad-spectrum serine protease inhibitor that inhibits MASP-2, MASP-1, thrombin, and plasmin. It is approved in Japan for the treatment of acute pancreatitis and disseminated intravascular coagulation. Its use in COVID-19 has been explored, with some clinical benefit reported in observational studies.

**Peptide-based inhibitors:**
- **C4-mimetic peptides:** Peptides derived from the C4 cleavage site (residues 750–765) act as competitive substrates. A cyclic peptide (cC4-1) with the sequence cyclo(CRNANRGC) inhibits MASP-2 with a Ki of 2 μM.
- **Exosite-binding peptides:** Phage display identified peptides that bind the CCP2 exosite, blocking C4 recognition without affecting the active site. These peptides have Ki values in the low micromolar range.

### 6.4 RNA-Based Therapeutics

**Antisense oligonucleotides (ASOs):** Gapmer ASOs targeting *MASP2* mRNA have been developed. IONIS-MASP2Rx is a second-generation ASO that reduces hepatic MASP-2 expression by 80% in non-human primates. Subcutaneous administration results in sustained knockdown for 4–6 weeks.

**siRNA conjugates:** GalNAc-conjugated siRNAs (e.g., ALN-MASP2) achieve hepatocyte-specific delivery via asialoglycoprotein receptor. A single dose reduces serum MASP-2 levels by >90% for 3 months in mice.

### 6.5 Gene Therapy

**CRISPR-Cas9 knockout:** Ex vivo CRISPR editing of *MASP2* in hepatocytes followed by autologous transplantation is theoretically feasible but faces challenges in delivery and engraftment efficiency.

**Base editing:** Adenine base editors (ABEs) can introduce the p.Asp120Gly mutation in *MASP2* to create a functional knockout. In vitro studies in HepG2 cells achieved 40% editing efficiency with minimal off-target effects.

### 6.6 Pharmacogenomic Considerations

The **p.Arg407His polymorphism (rs12711521)** affects drug response. Patients homozygous for the His allele have higher MASP-2 levels and may require higher doses of narsoplimab to achieve therapeutic inhibition. Conversely, patients with the Asp371Tyr polymorphism (reduced activity) may be more sensitive to MASP-2 inhibition, increasing bleeding risk due to coagulation crosstalk.

**Drug-drug interactions:** Nafamostat mesylate is metabolized by carboxylesterase 1 (CES1). Co-administration with CES1 inhibitors (e.g., clopidogrel) increases nafamostat exposure and bleeding risk.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 10747 | https://www.ncbi.nlm.nih.gov/gene/10747 |
| Ensembl | ENSG00000097774 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000097774 |
| UniProt | O00187 | https://www.uniprot.org/uniprotkb/O00187 |
| RCSB PDB | 1Q3X, 3P8O, 4FXG | https://www.rcsb.org/search?q=MASP2 |
| ClinVar | MASP2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=MASP2 |
| OMIM | 605102 | https://www.omim.org/entry/605102 |
| HGNC | 6907 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6907 |
| STRING | MASP2 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000264753 |
| BioGR

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)